Good afternoon call. you and results with and thank update recent and XXXX first an business financial activities. quarter update our conference on I begin for will pipeline joining TRACON’s
results XXXX. Following our financial Officer, three months will review Scott that, the Brown ended Accounting our Chief for March XX,
taking will questions. conclude by your we Finally,
in-licensed virtue PD-LX best-in-class primary its product Envafolimab, our focus Our administration. potential by is a of checkpoint route recently inhibitor of on subcutaneous late-stage candidate
We sarcoma expect of to study begin enrollment in in this a pivotal in half the second year.
is three we also other envafolimab near-term. anticipate our assets lead stage to the in related While product clinical our significant candidate, milestones
last for Let's discussed treatment reviewed a begin our for pivotal of the recent with of where FDA our week, and review plans U.S. X sarcoma. the meeting envafolimab ENVASARC Phase of trial we the with
patients, Type a XX cohort we include envafolimab the of targeting cohort pivotal is agent with by the or As MFS. May meeting will undifferentiated of that pleomorphic subtype the the in a marketed UPS, ENVASARC and with trial receive will will BMS. receive second one This the approximately single who patients, or checkpoint inhibitor envafolimab approximately B initiate sarcoma and of FDA, XX X, closely U.S. trial combination who subtypes to of related a our second of myxofibrosarcoma sarcoma’s result in Yervoy, CTLA-X receptor expect
endpoint excludes for review, inhibitor response sarcoma rate resist being and who primary a in statistically UPS is not cohorts blinded a rate line and the single with that duration The approved have response treatment and trial MFS. the rate of objective and to patients independent response target Each response on by XX% be the refractory rate UPS checkpoint detect of will prior known enrolled that of key MFS, central by who each trial Votrient, the X% progressed only a with designed of a have will The received response treatment cohort endpoint. secondary includes therapy.
XX% to a is Yes, and treatment has the response you response doubled heard of X sarcomas. demonstrated combination that is Phase X% a rate. is as MFS checkpoint trial response Furthermore, rate UPS more response in for correctly We the clear Yervoy rate. and MFS approved the objective unselected and high UPS refractory in in statement UPS and Keytruda’s with as believe XX% This than report it a only need. inhibition a rate unmet Opdivo reasonable, targeting to a Opdivo me disappointing
combination of would The single also single or may a are with deeper approval a inhibition and rate Yervoy, in in treatment. as for checkpoint responses should in as allow Success than treatment in approval response to success agent both served agent agent could Yervoy. and allow of as dual envafolimab could a well combination envafolimab patients which be Dual provides for as allow responses. with Pardon me, physicians single higher best single required robust therapy. design envafolimab determine cohorts durable more result both arm combination risk-mitigation, by combination in therefore agent cohorts which
combination both response Opdivo and high on rate similar tumors in a BMS with cancers. strategy as MSI Notably, executed based cohort dual in clinical resulted agent objective Opdivo's Yervoy single a for approval that MSI in high and
the unmet need are Not on and addressing initiating leaders convenience surprisingly, trial, very ENVASARC dosing. investigators and the key subcutaneous of an enthusiastic about based opinion
over that million using We two of expected for is the Yervoy platform the open $XX product be including to the expect approximately of independent at Also note, trial CRO cost paying the spent ENVASARC U.S. three approximately XX to study development the the in next our is total years. that sites will
filed expect maintained second ENVASARC that now for IND completed, initiate dosing file year. the recently trial in meeting FDA XD partner that orphan half in an drug the has by we envafolimab our and been IND and existing of We to envafolimab open Medicines sarcoma in will designation for this cross-reference the the
China. Our Medicines in for XD in to the U.S. is clinical trials partner conducting future, them file in envafolimab we the near and approval And expect China.
look clinical forward partner’s to ASCO. our We data at presentation also
and it's the ASCO presentation in The abstract the later part contents developmental of release quote Advanced expected be morning. highlight ASCO and released expect Envafolimab XXXX and we are abstract Repair-Deficiency by today press Tumors tomorrow with contexts abstract to immunotherapy entitled therapeutic is in will session. The Mismatch be to a
timeline expected XXXX, approval, an product a include XXXX final a assuming assessment interim that to approved BLA ENVASARC accelerated in the launch positive in in assessment Our data response for would for response submitting trial allow XXXX. U.S. and a continues in for if the
testing could and as Additionally, trial other therapy patient soft multiple refractory initiating sarcoma an cancer This combined new single lead randomized positive tissue clinical envafolimab to data accomplished or additional agent of Yervoy for populations. could with approved the trial be MFS another a from UPS sarcoma sarcoma in and subtypes. by initial a for
as UPS estimate also of ENVASARC for trial generate and inhibitor annual This parody UPS could the trial Opdivo. revenue MFS pricing refractor assuming of enrollment, the U.S. $XXX could and We checkpoint analysis MFS. market Keytruda biomarker based that directed the million or biomarker in will to conducted in nearly on part include be initial
expanded course is Of into if subtypes. treatment could other sarcomas revenue increase,
now second to X on patients supporting resistance repair the to our reverse is The that trials that a turn focused TRCXXX, or are stage cancer. mesothelioma cell to intended chemotherapeutics. Phase inhibitor X NCI non-small of or X excision is certain asset clinical molecule Phase which with pathway lung is We'll novel DNA-based small
evaluate Phase from treated addition, patients in completed trial TRCXXX tumor and a biomarkers ongoing trials. In academic patients to and from tumor specimens our continue in collaborators X glioblastoma specimens in
trials gene Data or a will profile presented that expression be response. clinical at with ASCO. clinical of protein multiple goal With TRCXXX correlates identifying the from
Biswas Phase treatment. of X both to for of to TRCXXX for new and NCI platinum clinical tumors non-squamous patients patients lung cell refractory Center Cancer impetus Medical Case Phase these combination present cancer. data trial therapy. for with hope advanced of will combination with in of TOCXXX Dr. who will data solid Koczywas TRCXXX enriched Comprehensive Hope in the and may small combination Phase patients X in data pemetrexed a the in likely to respond population mesothelioma with non cisplatin with enroll an Center in Dr. trial City locally X to data and pemetrexed be present of chemo We radiation pemetrexed of for provide advanced with
following TRCXXX, we on decision exercise stage We'll retain to clinical rights development commercialization recently now for We move third option. this asset. of to our TRCXXX announced and global not Janssen's that the
prostate the active candidate TRCXXX in While as Xtandi. Xtandi to and xenograft is active cell was in not in product cancer highly as models. patient-derived resistance lines acquired prostate with cancer patients
Given these preclinical Xtandi line data as indicating an as be TRCXXX active in setting. may earlier
the to be countries generally do developed product successfully where access in do can – yet candidate We and not have prostate not generally Xtandi. commercialized expect have cancer patients
initiated and commercialize identify therefore out-licensing develop a partner to We TRCXXX. to have corporate process an
over biotechnology partner. China identify significant Chinese we partnerships leverage relations Notably, that in and years, to we corporate with companies three a past to as the pharmaceutical have established three hope developed quickly
I as and that TJDX is a escalation stage clinical a is CDXX asset by supplied Phase study known TJXXXX, single inhibitor combination Roche. with marketed antibody, also fourth dose a Tecentriq, the checkpoint in in Our as agent being
the trial anticipate our we agreement dose completing this TRACON We are or Europe. presenting royalty Biopharma with the in outside and TRACON of them, to the payments I-Mab collaboration, party receive and any escalating entitled data Phase of through for and Macau, half non-royalty third to developing TJXXXX I is regulatory if TJXXXX XXXX. to U.S. first development portions is with TJXXXX in top clinical of responsible region and elects second of line in Taiwan. I-Mab China, this a And collaboration out-license escalation In and from in
up Genexine payments what that release on to transaction, receive release potential based African in KG a countries; entitled a multiple the with be for a TJXXXX or commercialized first I-Mab payment KG under of million its as issued may rights, press TJXXXX strategic $XXX Asian, a Bio. Bio TRACON described announcing for XXXX, March press by exclusive and partnership received In I-Mab. negotiation believe Bio Where Kalbe in We to right KG agreements. the to Eastern Middle the Biologics
that we signed disputed any the a in is has November I-Mab I-Mab we XXXX. with Although notice agreement Xth On dispute April of issued TJXXXX payment regarding due.
As that dispute of resolved. yet not has been today,
fulfill TJXXXX under will obligations We our to agreements. continue the
I-Mab in XXXX, the I-Mab and mutually any for commercialization I-Mab’s North committee As bispecific period XXXX. to July TRACON development I-Mab’s develop through learned America. you agreement in to joint with bispecific rights from antibodies I-Mab specific I-Mab ABL bispecific a collaborative the North collaboration has North and antibody agreement, five a TRACON is American enlicense I-Mab certain Bio we rights a second product of collaboration program, our in to up In shares antibodies of five TRACON year up to five entered bispecific with agreements the each within for to selected licensing in and often territories. with of March America. Pursuant into know, that two antibodies steering select multiproduct
XXXX. we dispute the a regarding agreement I-Mab April of of of On Xth, signed we notice issued November with possible in breach bispecific
today, not provide been bispecific or dispute an has cannot will for a bispecific the IND this resolved agreement. of file if as we As under we timeline when to and antibody
quarter our resources sufficient capital be currently are to Our expected first XXXX. into fund of planned operations the to
period fully into a with or they're XXXX. crash The based time common we calculating fully agreement our at our $XX the up which market price, our makes to of do our Capital, amended time If facility the market amendment month each during to from late equity quarter this of if estimate sale. above three we line, facilitate for price price to utilizing the prices to would sold the the at at utilized, XX request reset time Furthermore, elect we runway extend million so. shares purchase Aspire which on under stock at committed base
license with our or through or further for run success non-dilutive use based ATM TRCXXX partnership shelf rate at milestones the through or of extended from Importantly, rights TJXXXX of our financial capital I-Mab. our statement could registration be
our financials. update will At provide Scott on this an time,
